Venous thromboembolism in hospitalized patients with heart failure incidence, prognosis, and prevention

Circulation: Heart Failure

Volumn 3, Issue 1, 2010, Pages 165-173

  Ng, Tien M H ^a   Tsai, Fausan ^a   Khatri, Nudrat ^a   Barakat, Mohamad N ^a   Elkayam, Uri ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Anticoagulants; Heart failure; Prevention; Thrombosis

Indexed keywords

DALTEPARIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO;

CLINICAL TRIAL; COMPRESSION GARMENT; DRUG DOSE COMPARISON; DRUG EFFICACY; HEART FAILURE; HOSPITAL PATIENT; HUMAN; INCIDENCE; LOW DRUG DOSE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR; THROMBOSIS PREVENTION; TREATMENT DURATION; VENOUS THROMBOEMBOLISM; HOSPITALIZATION;

HEART FAILURE; HOSPITALIZATION; HUMANS; INCIDENCE; VENOUS THROMBOEMBOLISM;

EID: 76549104434     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.109.892349     Document Type: Review

References (93)

1. Rosamond W, Flegal K, Friday G, Furie K, Go A, Greenlund K, Haase N, Ho M, Howard V, Kissela B, Kittner S, Lloyd-Jones D, McDermott M, Meigs J, Moy C, Nichol G, O'Donnell CJ, Roger V, Rumsfeld J, Sorlie P, Steinberger J, Thom T, Wasserthiel-Smoller S, Hong Y. Heart disease and stroke statistics-2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2007;115: e69-e171.
2. Fang J, Mensah GA, Croft JB, Keenan NL. Heart failure-related hospi-talization in the US, 1979 to 2004. J Am Coll Cardiol. 2008;52:428-434.
3. Baker DW, Einstadter D, Thomas C, Cebul RD. Mortality trends for 23, 505 Medicare patients hospitalized with heart failure in Northeast Ohio, 1991 to 1997. Am Heart J. 2003;146:258-264.
4. Fonarow GC, Adams KF Jr, Abraham WT, Yancy CW, Boscardin WJ. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. J Am Med Assoc. 2005;293:572-580.
5. Alikhan R, Spyropoulos AC. Epidemiology of venous thromboembolism in cardiorespiratory and infectious disease. Am J Med. 2008;121:935-942.
6. Heit JA, O'Fallon WM, Petterson TM, Lohse CM, Silverstein MD, Mohr DN, Melton LJ III. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med. 2002;162:1245-1248.
7. Heit JA. Venous thromboembolism epidemiology: implications for prevention and management. Semin Thromb Hemost. 2002;28(suppl 2):3-13.
8. Pengo V, Lensing AW, Prins MH, Marchiori A, Davidson BL, Tiozzo F, Albanese P, Biasiolo A, Pegoraro C, Iliceto S, Prandoni P. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med. 2004;350:2257-2264.
9. Heit JA, Mohr DN, Silverstein MD, Petterson TM, O'Fallon WM, Melton LJ III. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med. 2000;160:761-768.
10. Cardiovascular Disease Educational and Research Trust; Cyprus Cardiovascular Disease Educational and Research Trust; European Venous Forum; International Surgical Thrombosis Forum; International Union of Angiology; Union Internationale de Phlébologie. Prevention and treatment of venous thromboembolism. International Consensus Statement (guidelines according to scientific evidence). Int Angiol. 2006;25:101-161.
11. Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 suppl): 381S-453S.
12. Kucher N, Spirk D, Kalka C, Mazzolai L, Nobel D, Banyai M, Frauchiger B, Bounameaux H. Clinical predictors of prophylaxis use prior to the onset of acute venous thromboembolism in hospitalized patients SWIss Venous ThromboEmbolism Registry (SWIVTER). J Thromb Haemost. 2008;6:2082-2087.
13. Peterman CM, Kolansky DM, Spinler SA. Prophylaxis against venous thromboembolism in acutely ill medical patients: an observational study. Pharmacotherapy. 2006;26:1086-1090.
14. Cohen AT, Tapson VF, Bergmann JF, Goldhaber SZ, Kakkar AK, Des-landes B, Huang W, Zayaruzny M, Emery L, Anderson FA Jr. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet. 2008;371:387-394.
15. Piazza G, Seddighzadeh A, Goldhaber SZ. Heart failure in patients with deep vein thrombosis. Am J Cardiol. 2008;101:1056-1059.
16. Jois-Bilowich P, Michota F, Bartholomew JR, Glauser J, Diercks D, Weber J, Fonarow GC, Emerman CL, Peacock WF IV; Adhere Scientific Advisory Committee and Investigators. Venous thromboembolism prophylaxis in hospitalized heart failure patients. J Card Fail. 2008;14:127-132.
17. Amin AN, Lin J, Yang G, Stemkowski S. Examining the rate of appropriate, ACCP-recommended VTE prophylaxis use in heart failure patients. J Card Fail. 2008;14: S83.
18. Alikhan R, Cohen AT, Combe S, Samama MM, Desjardins L, Eldor A, Janbon C, Leizorovicz A, Olsson CG, Turpie AG. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Arch Intern Med. 2004;164:963-968.
19. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ III. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 2000;160:809-815.
20. Weill-Engerer S, Meaume S, Lahlou A, Piette F, Saint-Jean O, Sachet A, Beinis JY, Gallinari C, Grancher AS, Vincent JP, Naga H, Belmin J, Salvatore R, Kazes M, Pautas E, Boiffin A, Piera JB, Duviquet M, Knafo D, Piau A, Miric D, Jean A, Bellamy V, Tissandier O, Le Blanche AF. Risk factors for deep vein thrombosis in inpatients aged 65 and older: a case-control multicenter study. J Am Geriatr Soc. 2004;52:1299-1304.
21. Howell MD, Geraci JM, Knowlton AA. Congestive heart failure and outpatient risk of venous thromboembolism: a retrospective, case-control study. J Clin Epidemiol. 2001;54:810-816.
22. Samama MM. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch Intern Med. 2000;160:3415-3420.
23. Fonarow GC, Corday E. Overview of acutely decompensated congestive heart failure (ADHF): a report from the ADHERE registry. Heart Fail Rev. 2004;9:179-185.
24. Irish AB, Green FR. Factor VII coagulant activity (VIIc) and hyperco-agulability in chronic renal disease and dialysis: relationship with dys-lipidaemia, inflammation, and factor VII genotype. Nephrol Dial Transplant. 1998;13:679-684.
25. Tveit DP, Hypolite IO, Hshieh P, Cruess D, Agodoa LY, Welch PG, Abbott KC. Chronic dialysis patients have high risk for pulmonary embolism. Am J Kidney Dis. 2002;39:1011-1017. (Pubitemid 34454219)
26. Cook D, Crowther M, Meade M, Rabbat C, Griffith L, Schiff D, Geerts W, Guyatt G. Deep venous thrombosis in medical-surgical critically ill patients: prevalence, incidence, and risk factors. Crit Care Med. 2005;33:1565-1571.
27. Hirsch DR, Ingenito EP, Goldhaber SZ. Prevalence of deep venous thrombosis among patients in medical intensive care. J Am Med Assoc. 1995;274:335-337.
28. Prandoni P, Bilora F, Marchiori A, Bernardi E, Petrobelli F, Lensing AW, Prins MH, Girolami A. An association between atherosclerosis and venous thrombosis. N Engl J Med. 2003;348:1435-1441.
29. Libertiny G, Hands L. Deep venous thrombosis in peripheral vascular disease. Br J Surg. 1999;86:907-910.
30. 29a. Ageno W, Becattini C, Brighton T, Selby R, Kamphuisen PW. Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation. 2008;117:93-102.
31. Darze ES, Latado AL, Guimaraes AG, Guedes RA, Santos AB, de Moura SS, Passos LC. Incidence and clinical predictors of pulmonary embolism in severe heart failure patients admitted to a coronary care unit. Chest. 2005;128:2576-2580.
32. Joffe HV, Kucher N, Tapson VF, Goldhaber SZ. Upper-extremity deep vein thrombosis: a prospective registry of 592 patients. Circulation. 2004;110:1605-1611.
33. Loh E, Sutton MS, Wun CC, Rouleau JL, Flaker GC, Gottlieb SS, Lamas GA, Moye LA, Goldhaber SZ, Pfeffer MA. Ventricular dysfunction and the risk of stroke after myocardial infarction. N Engl J Med. 1997;336:251-257.
34. Freudenberger RS, Hellkamp AS, Halperin JL, Poole J, Anderson J, Johnson G, Mark DB, Lee KL, Bardy GH. Risk of thromboembolism in heart failure: an analysis from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Circulation. 2007;115:2637-2641. (Pubitemid 46791362)
35. Lip GY, Gibbs CR. Does heart failure confer a hypercoagulable state? Virchow's triad revisited. J Am Coll Cardiol. 1999;33:1424-1426.
36. De Lorenzo F, Saba N, Kakkar VV. Blood coagulation in patients with chronic heart failure: evidence for hypercoagulable state and potential for pharmacological intervention. Drugs. 2003;63:565-576.
37. Gibbs CR, Blann AD, Watson RD, Lip GY. Abnormalities of hemorheo-logical, endothelial, and platelet function in patients with chronic heart failure in sinus rhythm: effects of angiotensin-converting enzyme inhibitor and beta-blocker therapy. Circulation. 2001;103:1746-1751.
38. Sbarouni E, Bradshaw A, Andreotti F, Tuddenham E, Oakley CM, Cleland JG. Relationship between hemostatic abnormalities and neuroen-docrine activity in heart failure. Am Heart J. 1994;127:607-612.
39. Lip GY, Lowe GD, Metcalfe MJ, Rumley A, Dunn FG. Effects of warfarin therapy on plasma fibrinogen, von Willebrand factor, and fibrin D-dimer in left ventricular dysfunction secondary to coronary artery disease with and without aneurysms. Am J Cardiol. 1995;76:453-458.
40. Torre-Amione G, Kapadia S, Benedict C, Oral H, Young JB, Mann DL. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol. 1996;27:1201-1206.
41. Kubo SH, Rector TS, Bank AJ, Williams RE, Heifetz SM. Endothe-lium-dependent vasodilation is attenuated in patients with heart failure. Circulation. 1991;84:1589-1596.
42. Jafri SM, Ozawa T, Mammen E, Levine TB, Johnson C, Goldstein S. Platelet function, thrombin and fibrinolytic activity in patients with heart failure. Eur Heart J. 1993;14:205-212.
43. Beemath A, Stein PD, Skaf E, Al Sibae MR, Alesh I. Risk of venous thromboembolism in patients hospitalized with heart failure. Am J Cardiol. 2006;98:793-795. (Pubitemid 44301013)
44. Alikhan R, Cohen AT, Combe S, Samama MM, Desjardins L, Eldor A, Janbon C, Leizorovicz A, Olsson CG, Turpie AG. Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study. Blood Coagul Fibrinolysis. 2003;14:341-346.
45. Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus PT, Goldhaber SZ. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation. 2004;110:874-879.
46. Cohen AT, Davidson BL, Gallus AS, Lassen MR, Prins MH, Tomkowski W, Turpie AG, Egberts JF, Lensing AW. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ. 2006;332:325-329.
47. Samama MM, Cohen AT, Darmon JY, Desjardins L, Eldor A, Janbon C, Leizorovicz A, Nguyen H, Olsson CG, Turpie AG, Weisslinger N. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med. 1999;341:793-800.
48. Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet. 1999;353:1386-1389.
49. Goldhaber SZ, Tapson VF. A prospective registry of 5, 451 patients with ultrasound-confirmed deep vein thrombosis. Am J Cardiol. 2004;93:259-262.
50. Grubman EM, Pavri BB, Shipman T, Britton N, Kocovic DZ. Cardiac death and stored electrograms in patients with third-generation implantable cardioverter-defibrillators. J Am Coll Cardiol. 1998;32:1056-1062.
51. Roberts WC, Siegel RJ, McManus BM. Idiopathic dilated cardiomyopa-thy: analysis of 152 necropsy patients. Am J Cardiol. 1987;60:1340-1355.
52. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. J Am Med Assoc. 1995;273:1450-1456.
53. Darze ES, Latado AL, Guimaraes AG, Guedes RA, Santos AB, de Moura SS, Passos LC. Acute pulmonary embolism is an independent predictor of adverse events in severe decompensated heart failure patients. Chest. 2007;131:1838-1843.
54. Gallus AS, Hirsh J, Tutle RJ, Trebilcock R, O'Brien SE, Carroll JJ, Minden JH, Hudecki SM. Small subcutaneous doses of heparin in prevention of venous thrombosis. N Engl J Med. 1973;288:545-551.
55. Belch JJ, Lowe GD, Ward AG, Forbes CD, Prentice CR. Prevention of deep vein thrombosis in medical patients by low-dose heparin. Scott Med J. 1981;26:115-117.
56. Halkin H, Goldberg J, Modan M, Modan B. Reduction of mortality in general medical in-patients by low-dose heparin prophylaxis. Ann Intern Med. 1982;96:561-565.
57. Cade JF. High risk of the critically ill for venous thromboembolism. Crit Care Med. 1982;10:448-450.
58. Gardlund B. Randomised, controlled trial of low-dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases. The Heparin Prophylaxis Study Group. Lancet. 1996;347:1357-1361.
59. Mismetti P, Laporte-Simitsidis S, Tardy B, Cucherat M, Buchmuller A, Juillard-Delsart D, Decousus H. Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomised clinical trials. Thromb Haemost. 2000;83:14-19.
60. Spyropoulos AC. Emerging strategies in the prevention of venous throm-boembolism in hospitalized medical patients. Chest. 2005;128:958-969.
61. Cohen AT, Turpie AG, Leizorovicz A, Olsson CG, Vaitkus PT, Goldhaber SZ. Thromboprophylaxis with dalteparin in medical patients: which patients benefit? Vasc Med. 2007;12:123-127.
62. McGarry LJ, Thompson D. Retrospective database analysis of the prevention of venous thromboembolism with low-molecular-weight heparin in acutely III medical inpatients in community practice. Clin Ther. 2004;26:419-430.
63. Kanaan AO, Silva MA, Donovan JL, Roy T, Al-Homsi AS. Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients. Clin Ther. 2007;29:2395-2405.
64. Harenberg J, Kallenbach B, Martin U, Dempfle CE, Zimmermann R, Kubler W, Heene DL. Randomized controlled study of heparin and low molecular weight heparin for prevention of deep-vein thrombosis in medical patients. Thromb Res. 1990;59:639-650.
65. Lechler E, Schramm W, Flosbach CW. The venous thrombotic risk in non-surgical patients: epidemiological data and efficacy/safety profile of a low-molecular-weight heparin (enoxaparin). The Prime Study Group. Haemostasis. 1996;26(suppl 2):49-56.
66. Bergmann JF, Neuhart E. A multicenter randomized double-blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in-patients bedridden for an acute medical illness. The Enoxaparin in Medicine Study Group. Thromb Haemost. 1996;76:529-534.
67. Harenberg J, Roebruck P, Heene DL. Subcutaneous low-molecular-weight heparin versus standard heparin and the prevention of thrombo-embolism in medical inpatients. The Heparin Study in Internal Medicine Group. Haemostasis. 1996;26:127-139.
68. Kleber FX, Witt C, Vogel G, Koppenhagen K, Schomaker U, Flosbach CW. Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. Am Heart J. 2003;145:614-621.
69. McGarry LJ, Stokes ME, Thompson D. Outcomes of thromboprophylaxis with enoxaparin vs. unfractionated heparin in medical inpatients. Thromb J. 2006;4:17.
70. Dentali F, Douketis JD, Gianni M, Lim W, Crowther MA. Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboem-bolism in hospitalized medical patients. Ann Intern Med. 2007;146:278-288.
71. Tapson VF, Decousus H, Pini M, Chong BH, Froehlich JB, Monreal M, Spyropoulos AC, Merli GJ, Zotz RB, Bergmann JF, Pavanello R, Turpie AG, Nakamura M, Piovella F, Kakkar AK, Spencer FA, Fitzgerald G, Anderson FA Jr. Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the International Medical Prevention Registry on Venous Thromboembolism. Chest. 2007;132:936-945.
72. 70a. Kierkegaard A, Norgren L. Graduated compression stockings in the prevention of deep vein thrombosis in patients with acute myocardial infarction. Eur Heart J. 1993;14:1365-1368.
73. Agu O, Hamilton G, Baker D. Graduated compression stockings in the prevention of venous thromboembolism. Br J Surg. 1999;86:992-1004.
74. Amaragiri SV, Lees TA. Elastic compression stockings for prevention of deep vein thrombosis. Cochrane Database Syst Rev. 2000: CD001484.
75. Imperiale TF, Speroff T. A meta-analysis of methods to prevent venous thromboembolism following total hip replacement. J Am Med Assoc. 1994;271:1780-1785.
76. Kakkos SK, Caprini JA, Geroulakos G, Nicolaides AN, Stansby GP, Reddy DJ. Combined intermittent pneumatic leg compression and pharmacological prophylaxis for prevention of venous thrombo-embolism in high-risk patients. Eur J Vasc Endovasc Surg. 2009;37:364-365.
77. Hull RD, Schellong SM, Tapson VF, Monreal M, Samama MM, Turpie AG, Wildgoose P, Yusen RD. Extended-duration thromboprophylaxis in acutely ill medical patients with recent reduced mobility: methodology for the EXCLAIM study. J Thromb Thrombolysis. 2006;22:31-38.
78. Hull RD, Schellong SM, Tapson VF. Extended-duration venous throm-boembolism prophylaxis in acutely ill medical patients with recent reduced morbility: the EXCLAIM Study. J Thromb Haemost. 2007;5(suppl 2): O-S-001.
79. Kahn SR, Panju A, Geerts W, Pineo GF, Desjardins L, Turpie AG, Glezer S, Thabane L, Sebaldt RJ. Multicenter evaluation of the use of venous thromboembolism prophylaxis in acutely ill medical patients in Canada. Thromb Res. 2007;119:145-155.
80. Dexter PR, Perkins S, Overhage JM, Maharry K, Kohler RB, McDonald CJ. A computerized reminder system to increase the use of preventive care for hospitalized patients. N Engl J Med. 2001;345:965-970.
81. Lecumberri R, Marques M, Diaz-Navarlaz MT, Panizo E, Toledo J, Garcia-Mouriz A, Paramo JA. Maintained effectiveness of an electronic alert system to prevent venous thromboembolism among hospitalized patients. Thromb Haemost. 2008;100:699-704.
82. Kucher N, Koo S, Quiroz R, Cooper JM, Paterno MD, Soukonnikov B, Goldhaber SZ. Electronic alerts to prevent venous thromboembolism among hospitalized patients. N Engl J Med. 2005;352:969-977.
83. Sobieraj DM. Development and implementation of a program to assess medical patients' need for venous thromboembolism prophylaxis. Am J Health Syst Pharm. 2008;65:1755-1760.
84. Durieux P, Nizard R, Ravaud P, Mounier N, Lepage E. A clinical decision support system for prevention of venous thromboembolism: effect on physician behavior. J Am Med Assoc. 2000;283:2816-2821.
85. Baroletti S, Munz K, Sonis J, Fanikos J, Fiumara K, Paterno M, Goldhaber SZ. Electronic alerts for hospitalized high-VTE risk patients not receiving prophylaxis: a cohort study. J Thromb Thrombolysis. 2008;25:146-150.
86. McMullin J, Cook D, Griffith L, McDonald E, Clarke F, Guyatt G, Gibson J, Crowther M. Minimizing errors of omission: behavioural reen-forcement of heparin to avert venous emboli: the BEHAVE study. Crit Care Med. 2006;34:694-699.
87. Piazza G, Rosenbaum EJ, Pendergast W, Jacobson JO, Pendleton RC, McLaren GD, Elliott CG, Stevens SM, Patton WF, Dabbagh O, Paterno MD, Catapane E, Li Z, Goldhaber SZ. Physician alerts to prevent symptomatic venous thromboembolism in hospitalized patients. Circulation. 2009;119:2196-2201.
88. Shedd GC, Franklin C, Schumacher AM, Green DE. Improving inpatient venous thromboembolism prophylaxis. South Med J. 2008;101:1209-1215.
89. Anderson FA Jr, Wheeler HB, Goldberg RJ, Hosmer DW, Forcier A, Patwardhan NA. Changing clinical practice. Prospective study of the impact of continuing medical education and quality assurance programs on use of prophylaxis for venous thromboembolism. Arch Intern Med. 1994;154:669-677.
90. Dobesh PP, Stacy ZA. Effect of a clinical pharmacy education program on improvement in the quantity and quality of venous thromboembolism prophylaxis for medically ill patients. J Manag Care Pharm. 2005;11:755-762.
91. Stinnett JM, Pendleton R, Skordos L, Wheeler M, Rodgers GM. Venous thromboembolism prophylaxis in medically ill patients and the development of strategies to improve prophylaxis rates. Am J Hematol. 2005;78:167-172.
92. Schuerer DJ, Whinney RR, Freeman BD, Nash J, Prasad S, Krem MM, Mazuski JE, Buchman TG. Evaluation of the applicability, efficacy, and safety of a thromboembolic event prophylaxis guideline designed for quality improvement of the traumatically injured patient. J Trauma. 2005;58:731-739.
93. Tooher R, Middleton P, Pham C, Fitridge R, Rowe S, Babidge W, Maddern G. A systematic review of strategies to improve prophylaxis for venous thromboembolism in hospitals. Ann Surg. 2005;241:397-415.